(2-chloro-ethyl)-[3-(2-chloro-ethyl)-[1,3,2]oxazaphosphinan-2-yl]-amine | 74857-12-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧氮杂膦
• 英文名称: (2-chloro-ethyl)-[3-(2-chloro-ethyl)-[1,3,2]oxazaphosphinan-2-yl]-amine
• 英文别名: N,3-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine
• CAS: 74857-12-8
• 化学式: C₇H₁₅Cl₂N₂OP
• 分子量: 245.089
• InChiKey: BSPRWDJTHANXLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• SPIRO-OXINDOLE MDM2 ANTAGONISTS
  申请人：Wang Shaomeng

  公开号：US20120122947A1

  公开（公告）日：2012-05-17

  Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.

  本文提供了关于药物化学领域的化合物、组合物和方法。这里提供的化合物和组合物涉及螺环氧吲哚，其作为p53和MDM2相互作用的拮抗剂，并且它们作为治疗癌症和其他疾病的药物的用途。
• DIAZO BICYCLIC SMAC MIMETICS AND THE USES THEREOF
  申请人：Wang Shaomeng

  公开号：US20100273812A1

  公开（公告）日：2010-10-28

  The invention relates to diazo bicyclic mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.

  该发明涉及一种Smac的重氮双环模拟物，其作为细胞凋亡抑制蛋白抑制剂。该发明还涉及利用这些模拟物诱导细胞凋亡死亡以及使细胞对凋亡诱导剂敏感的用途。
• MAGNETIC NANOSTRUCTURES AS THERANOSTIC AGENTS
  申请人：Dravid Vinayak P.

  公开号：US20120308657A1

  公开（公告）日：2012-12-06

  The present invention relates to magnetic nanostructures as theranostic agents, which provide dual function as diagnostic and therapeutic agents. In particular, the present invention relates to compositions comprising magnetic nanostructures and their use as targeted therapeutic agents for cancers (e.g., medulloblastoma) and Alzheimer's disease and related diseases and conditions.

  本发明涉及磁性纳米结构作为治疗诊断剂，其具有诊断和治疗的双重功能。具体而言，本发明涉及包含磁性纳米结构的组合物及其作为针对癌症（例如髓母细胞瘤）和阿尔茨海默病以及相关疾病和病况的靶向治疗剂的使用。
• DIMETHYL-NONATETRAENYL-TRIMETHYL-CYCLOHEXYL COMPOUNDS AND USES THEREOF
  申请人：The Regents of the University of Michigan

  公开号：US20180339961A1

  公开（公告）日：2018-11-29

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a dimethyl-nonatetraenyl-trimethyl-cyclohexyl structure useful as therapeutics for the treatment of subjects suffering from disorders characterized by abnormal proliferation and/or abnormal differentiation of cells, in particular of cells of which the growth and differentiation is sensitive to the actions of retinoids.

  这项发明属于药物化学领域。具体而言，本发明涉及一类新型小分子，其具有二甲基-九十三烯基-三甲基-环己基结构，可用作治疗患有细胞异常增殖和/或异常分化的疾病患者的治疗剂，特别是对于对视黄醇类物质敏感的细胞的生长和分化。
• ERG TARGETED THERAPY
  申请人：The Regents of the University of Michigan

  公开号：US20180273595A1

  公开（公告）日：2018-09-27

  The present disclosure relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present disclosure relates to recurrent gene fusions as clinical targets for cancer.

  本公开涉及癌症治疗的组合物和方法，包括但不限于针对癌症标志物的靶向抑制。特别是，本公开涉及将复发性基因融合作为癌症的临床靶点。